March 10, 2023
Astellas Pharma said on March 9 that its acute myeloid leukemia (AML) drug Xospata (gilteritinib) missed the primary goal in a PIII study exploring its use as a maintenance therapy for certain patients after allogeneic hematopoietic stem cell transplantation (HSCT)...read more